It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Nebulin is a giant protein that winds around the actin filaments in the skeletal muscle sarcomere. Compound-heterozygous mutations in the nebulin gene (NEB) cause typical nemaline myopathy (NM), a muscle disorder characterized by muscle weakness with limited treatment options. We created a mouse model with a missense mutation p.Ser6366Ile and a deletion of NEB exon 55, the Compound-Het model that resembles typical NM. We show that Compound-Het mice are growth-retarded and have muscle weakness. Muscles have a reduced myofibrillar fractional-area and sarcomeres are disorganized, contain rod bodies, and have longer thin filaments. In contrast to nebulin-based severe NM where haplo-insufficiency is the disease driver, Compound-Het mice express normal amounts of nebulin. X-ray diffraction revealed that the actin filament is twisted with a larger radius, that tropomyosin and troponin behavior is altered, and that the myofilament spacing is increased. The unique disease mechanism of nebulin-based typical NM reveals novel therapeutic targets.
Nebulin-based nemaline myopathy is a heterogenous disease with unclear pathological mechanisms. Here, the authors generate a mouse model that mimics the most common genetic cause of the disease and demonstrate that muscle weakness in this model is associated with twisted actin filaments and altered tropomyosin and troponin behaviour.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Li, Frank 1 ; Hernandez Yaeren 1 ; Kolb, Justin 1 ; Kiss Balazs 1 ; Tonino Paola 1 ; van der Pijl Robbert 1 ; Karimi Esmat 1 ; Gong, Henry 2 ; Strom, Josh 1 ; Hourani Zaynab 1 ; Smith, John E, III 1
; Ottenheijm Coen 1 ; Irving, Thomas 2 ; Granzier Henk 3
1 University of Arizona, Department of Cellular and Molecular Medicine, Tucson, USA (GRID:grid.134563.6) (ISNI:0000 0001 2168 186X)
2 Department of Biology, Illinois Institute of Technology, Chicago, USA (GRID:grid.62813.3e) (ISNI:0000 0004 1936 7806)
3 University of Arizona, Department of Cellular and Molecular Medicine, Tucson, USA (GRID:grid.134563.6) (ISNI:0000 0001 2168 186X); University of Arizona, Sarver Molecular Cardiovascular Research Program, Tucson, USA (GRID:grid.134563.6) (ISNI:0000 0001 2168 186X)




